Skip Navigation

The Children's Mercy Hospital

Blood and Marrow Transplant Program
2401 Gillham Road
Kansas City, MO 64118
(816) 234-3265
(800) 236-1713
http://www.childrensmercy.org/Clinics_and_Services

Number of Transplants Performed

This center has been performing allogeneic transplants since 1994 and has been an NMDP transplant center since February 2007.

Transplants Reported (From Jan. 2011 to Dec. 2012 as reported by the centers)       Unrelated or Related Donor Auto-
logous

(PBSC or marrow)
Total (by transplant type)
Marrow PBSC Cord
Blood
Unrelated Donor
- Adult
0 1 0 --- 1
Unrelated Donor
- Pediatric
10 1 12 --- 23
Related Donor
- Adult
0 0 0 --- 0
Related Donor
- Pediatric
11 1 0 --- 12
Autologous
- Adult
--- --- --- 0 0
Autologous
- Pediatric
--- --- --- 19 19
Total
(by cell source)
21 3 12 19 55

To find centers that perform cord blood transplants, use the Search Tool on this site.


Patient Survival Information for this Center

The Children's Mercy Hospitals and Clinics


This center's actual 1-year survival results are similar to the expected rate for this center.

The survival information we have for this center includes ONLY:

  1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2009, 2010 and 2011, and
  2. Who had their transplant at a U.S. transplant center, and
  3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 47 patients.

The actual 1-year survival of these patients is 72.3%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 64.7% and 88.0%.

For help with understanding these statistics, please see Understanding Transplant Outcomes (PDF).


Transplant Results by Patient's Age, Disease Type and Stage

The Children's Mercy Hospital - Related

Survival by Patient's Age, Disease Type and Stage after Related Donor Transplantation

This report is based on first allogeneic transplants performed between January 2009 and December 2011 using related donors. It only includes patients with known survival status at 1-year post-transplant. In some cases, patients may have been alive at last reported follow-up that was less than one year. Those patients have not been included in this report. The first number represents the number of patients alive at one year post transplant. The second number is a total number of transplanted patients in that particular group.


Diagnosis 0-9 Yrs 10-19 Yrs 20-29 Yrs 30-39 Yrs 40-49 Yrs 50-59 Yrs 60+ Yrs Overall
Acute lymphoblastic leukemia in first complete remission -- 1/1 -- -- -- -- -- 1/1
Acute lymphoblastic leukemia in second complete remission 2/2 -- -- -- -- -- -- 2/2
Acute lymphoblastic leukemia in third or higher complete remission, relapse, or primary induction failure -- 2/2 -- -- -- -- -- 2/2
Acute myelogenous leukemia in first complete remission 1/1 3/3 -- -- -- -- -- 4/4
Acute myelogenous leukemia in second complete remission 1/1 -- -- -- -- -- -- 1/1
Acute myelogenous leukemia in third or higher complete remission, relapse, or primary induction failure 1/1 -- -- -- -- -- -- 1/1
Disorders of the immune system 1/1 -- -- -- -- -- -- 1/1
Inherited abnormalities of erythrocyte differentiation or function 1/1 -- -- -- -- -- -- 1/1
Inherited disorders of metabolism 1/1 -- -- -- -- -- -- 1/1
Severe aplastic anemia 1/1 1/1 -- -- -- -- -- 2/2
Total 9/9 7/7 -- -- -- -- -- 16/16

The Children's Mercy Hospital - Unrelated

Survival by Patient's Age, Disease Type and Stage after Unrelated Donor Transplantation

This report is based on first allogeneic transplants performed between January 2009 and December 2011 using unrelated donors. It only includes patients with known survival status at 1-year post-transplant. In some cases, patients may have been alive at last reported follow-up that was less than one year. Those patients have not been included in this report. The first number represents the number of patients alive at one year post transplant. The second number is a total number of transplanted patients in that particular group.


Diagnosis 0-9 Yrs 10-19 Yrs 20-29 Yrs 30-39 Yrs 40-49 Yrs 50-59 Yrs 60+ Yrs Overall
Acute lymphoblastic leukemia in first complete remission 1/1 1/1 -- -- -- -- -- 2/2
Acute lymphoblastic leukemia in second complete remission 2/4 -- -- -- -- -- -- 2/4
Acute lymphoblastic leukemia in third or higher complete remission, relapse, or primary induction failure 1/1 0/1 -- -- -- -- -- 1/2
Acute myelogenous leukemia in first complete remission 0/1 1/2 -- -- -- -- -- 1/3
Acute myelogenous leukemia in second complete remission 1/3 1/1 -- -- -- -- -- 2/4
Acute myelogenous leukemia in third or higher complete remission, relapse, or primary induction failure -- 0/1 -- -- -- -- -- 0/1
Disorders of the immune system 1/1 -- -- -- -- -- -- 1/1
Histiocytic disorders 0/1 1/1 -- -- -- -- -- 1/2
Hodgkin lymphoma -- -- 1/1 -- -- -- -- 1/1
Inherited abnormalities of erythrocyte differentiation or function 1/1 -- -- -- -- -- -- 1/1
Inherited disorders of metabolism 0/1 -- -- -- -- -- -- 0/1
Myelodysplastic disorders - Refractory anemia, Refractory anemia with ringed sideroblast, Refractory cytopenia with multilineage dysplasia, Refractory cytopenia with multilineage dysplasia and ringed sideroblast -- 0/1 -- -- -- -- -- 0/1
Myelodysplastic disorders - Refractory Anemia with excess blasts (with 5-9% brasts (RAEB-1) and 10-19% blasts (RAEB-2)) -- 2/2 -- -- -- -- -- 2/2
Myeloproliferative syndromes 1/2 -- -- -- -- -- -- 1/2
Severe aplastic anemia 1/1 0/1 -- -- -- -- -- 1/2
Total 9/17 6/11 1/1 -- -- -- -- 16/29

Program Description:

The Children's Mercy Hospital Blood and Marrow Transplant Program treats children and young adults. The program performs transplants for patients with a variety of childhood cancers including leukemia, lymphoma, and solid childhood tumors. They also transplant patients with a diagnosis of aplastic anemia, sickle cell disease, immunodeficiencies, and other hematologic, metabolic, or autoimmune disorders, utilizing all donor sources.

Contact Information:

If you have transplant-related questions, please contact Karen Kranz, transplant center coordinator, at (816) 302-6814 or by e-mail at kakranz@cmh.edu.

Program Type:

Pediatric

Attending Physicians:

(Medical Doctors)

Pediatric -

Ibrahim Ahmed, Jignesh Dalal, Michelle Manalang, G. Doug Myers, Mohamed Radhi

Transplants Performed:

Marrow/PBSC, single cord, and double cord

Cord blood transplants performed on:

Pediatric only

Find research trials at this center here:

ClinicalTrials.gov

Estimated Search & Transplant Costs

The costs for a transplant vary greatly from center to center and depend on factors such as health insurance, disease type and disease stage of the patient, as well as center-specific billing policies. Examples of costs in the search and transplant include:

  • The amount and geographic location of donors tested
  • Testing needed to confirm a match
  • Processing and collecting of tissue-typing samples
  • Donor workup testing needed
  • Getting the marrow, PBSC or cord blood unit for transplant

For the best understanding of costs of transplant and follow-up for a specific transplant center, contact the center's Financial Representative.

help Explain Transplant Costs at Different Centers

Resources for financial information

If you have questions about costs and financial services at this transplant center, you can contact the center's financial representative

Financial services at this center could include:

  • Health insurance information
  • Financial assistance
  • Patient-related resources

Additional Information

Further information about this center, including the number and type of transplants performed in each of the last three years, and the support groups offered, may be found in the BMT InfoNet Transplant Center Directory:
http://www.bmtinfonet.org/transplantcenters.

BMT InfoNet (Blood & Marrow Transplant Information Network) is a nonprofit organization that provides information and emotional support to transplant patients and their families.